Clinical Trials Logo

Ulcer clinical trials

View clinical trials related to Ulcer.

Filter by:

NCT ID: NCT05404074 Recruiting - Ulcerative Colitis Clinical Trials

Pharmacokinetics of Cobitolimod Enemas in Participants With Active Ulcerative Colitis

Start date: November 22, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the PK, safety and tolerability of cobitolimod ememas (500mg/50mL) given to participants with active left-sided UC.

NCT ID: NCT05382715 Recruiting - Colitis, Ulcerative Clinical Trials

A Study to Evaluate the Utilization, Effectiveness, and Quality of Life of Ozanimod in Participants With Ulcerative Colitis

COLIBRI
Start date: May 30, 2022
Phase:
Study type: Observational

The purpose of this study is to monitor the use, effectiveness and treatment persistence with Ozanimod (Zeposia®) as well as quality of life in participants undergoing treatment for moderate-to-severe ulcerative colitis (UC).

NCT ID: NCT05377580 Recruiting - Clinical trials for Ulcerative Colitis (UC)

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.

NCT ID: NCT05370885 Recruiting - Ulcerative Colitis Clinical Trials

VE202 in Patients With Mild-to-Moderate Ulcerative Colitis

Start date: May 8, 2023
Phase: Phase 2
Study type: Interventional

A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

NCT ID: NCT05369832 Recruiting - Colitis, Ulcerative Clinical Trials

An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice

Start date: December 16, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to explore the safety, efficacy, effects on quality of life (QOL), and biomarker response of ozanimod in participants with moderate to severely active ulcerative colitis (UC) in clinical practice.

NCT ID: NCT05327790 Recruiting - Ulcerative Colitis Clinical Trials

LFMT vs Placebo in New Biologic Start for Ulcerative Colitis

Start date: June 3, 2022
Phase: Phase 2
Study type: Interventional

To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.

NCT ID: NCT05322525 Recruiting - Clinical trials for Venous Leg Ulcers (VLU)

A Research Study to Evaluate the Safety and Potential Efficacy of ON101 Cream for the Treatment of Venous Leg Ulcers.

Start date: June 23, 2021
Phase: Phase 4
Study type: Interventional

A Research Study to evaluate the safety and potential efficacy of ON101 cream for the treatment of venous leg ulcers.The objectives of the study are to determine the safety and to explore the potential efficacy of ON101 cream in patients with venous leg ulcers.

NCT ID: NCT05321485 Recruiting - Ulcerative Colitis Clinical Trials

The Effect of MedicijnWijs on Adherence to Azathioprine Therapy in Adolescents With IBD

MEDICATION
Start date: March 16, 2022
Phase: N/A
Study type: Interventional

Medication non-adherence is an existing problem in patients with inflammatory bowel diseases (IBD). Adherence rates are especially low in children and adolescents. Good medication adherence is key in achieving lower disease activity and longer periods of remission. Previous research has shown education can increase medication adherence. MedicijnWijs is a mobile phone app containing a module concerning a 6-weeks guidance with azathioprine therapy. It provides information about IBD and azathioprine. In this multicenter before-and-after study, the aim is to assess the effect of MedicijnWijs on the adherence to azathioprine therapy in adolescents with IBD. This is done using two validated questionnaires that are translated to Dutch: the Medication Adherence Report Scale-5 (MARS-5), which tests the participants' adherence to azathioprine therapy, and the Inflammatory Bowel Disease Knowledge Inventory Device 2 (IBD-KID2), which tests the participants' knowledge about IBD. These questionnaires are filled in at the beginning of the study period and after 6 weeks of using MedicijnWijs. This way a change in both scores can be assessed. The investigators hypothesize that MedicijnWijs will help increase the adherence to azathioprine therapy in adolescents with IBD.

NCT ID: NCT05319106 Recruiting - Venous Leg Ulcer Clinical Trials

Phase Ⅱ Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Venous Leg

Start date: December 15, 2022
Phase: N/A
Study type: Interventional

This project adopts a prospective clinical trial study to compare and evaluate the efficacy of local transplantation of human umbilical cord mesenchymal stem cells combined with silver ion dressing and simple silver ion dressing in the treatment of venous lower extremity ulcer wounds. To improve the healing rate and quality of life of patients.

NCT ID: NCT05313828 Recruiting - Corneal Ulcer Clinical Trials

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

Start date: March 18, 2022
Phase:
Study type: Observational

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK. In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.